Uncategorized-EN

July is the month of #SarcomaAwareness! We at SPAEN fight for a better situation for sarcoma, GIST, bonecancer and desmoid patients – together with our member groups, patients & advocates, experts & healthcare professionals. Stronger together!! We are here for you!    “Sarcoma Awareness Month 2020” What are sarcomas? A sarcoma is a cancer which…

13th of July is GIST Awareness Day, and SPAEN is encouraging everyone to help bring attention to GIST and other rare cancers. The theme of GIST Awareness Day this year is HOPE! 2020 brought a global health crisis that has challenged GIST patients. This year’s GIST Awareness Day is dedicated to Nikhil Guhagarkar, our beloved…

End of September, a new therapy option for GIST patients with D842V mutation was approved for the EU: Avapritinib (Ayvakyt®) from Blueprint Medicines is a highly selective tyrosine kinase inhibitor. It is directed against the D842V mutation in exon 18, which has been shown to be resistant to all drugs available to date. The approval…

SOS Desmoide France will hold its first webconference Saturday, January 30, 2021, from 9:30 to 12:00 AM Paris time. It is free and open for everybody, patients, relatives, physicians. You will have the opportunity to hear respected experts explain how desmoid tumors are treated in France, present the research projects that SOS Desmoid decided to…

European Commission Grants Lilly’s olaratumab (LARTRUVOTM), in Combination with Doxorubicin, Approval for the Treatment of Advanced Soft Tissue Sarcoma in Europe Olaratumab, in combination with doxorubicin, is the first front-line therapy approved in four decades for advanced soft tissue sarcoma in Europe JGDG study showed olaratumab, in combination with doxorubicin, offered a median 11.8-month increase…

The following table lists the results of some of the many clinical trials available worldwide for sarcoma, GIST or desmoid patients. For more information about some of the ongoing trials, click here. No Trial Name Agents Phase Status Results Sponsor 1 Study 62005 Imatinib in twodifferent dosings III Closed Results Study 62005 EORTC Note: The…

Ten-year progression-free and overall survival in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). Long-term analysis of the EORTC, ISG, AGITG intergroup Phase III randomized trial on imatinib at two dose levels. HOW MANY patients participated? A total of 946 patients at 56 centers in 13 countries in Europe and Australia/New Zealand/Singapore took part…

Clinical studies are an essential step in the development of novel treatment methods for cancer and other diseases. They show researchers what works for the welfare of patients and what does not. In addition to safety and effectiveness they also determine whether the side effects of a new treatment are acceptable and, increasingly, what quality…